Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern-Reference-Cited by-同舟云学术

Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern

Published:2024-03-20 Issue:5 Volume:20 Page:314-314
ISSN:1759-5029
Container-title:Nature Reviews Endocrinology
language:en
Short-container-title:Nat Rev Endocrinol

Author:

De Sousa Sunita M. C.^ORCID,Jukes Alistair K.,Candy Nicholas G.,Chapman Ian M.,Torpy David J.,Shivalingam Brindha,Wormald Peter-John,Santoreneos Stephen

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41574-024-00976-y.pdf

Reference10 articles.

1. Petersenn, S. et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat. Rev. Endocrinol. 19, 722–740 (2023).

2. De Sousa, S. M. C. et al. Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J. Clin. Endocrinol. Metab. 105, dgz076 (2020).

3. De Sousa, S. M. C. Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management? Endocr. Oncol. 2, R31–R50 (2022).

4. Gillam, M. P., Molitch, M. E., Lombardi, G. & Colao, A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485–534 (2006).

5. Landolt, A. M., Keller, P. J., Froesch, E. R. & Mueller, J. Bromocriptine: Does it jeopardise the result of later surgery for prolactinomas? Lancet 2, 657–658 (1982).

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Medical and Surgical Treatment in Management of the Patients With Prolactinoma: A Single-Center Experience;Experimental and Clinical Endocrinology & Diabetes;2024-07-11

2. Reply to ‘Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern’;Nature Reviews Endocrinology;2024-03-20